March 23, 2007 17:49 ET

AtheroGenics Schedules Conference Call and Webcast to Discuss ARISE Phase III Clinical Trial Results

ATLANTA, GA--(CCNMatthews - March 23, 2007) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it will host a conference call and webcast to discuss key clinical findings from the ARISE Phase III trial of AGI-1067 on Tuesday, March 27, 2007, at 4:00 PM EDT.

ARISE study results are scheduled to be presented by Jean-Claude Tardif, M.D., Director of Research; Professor of Medicine, Montreal Heart Institute; and Marc Pfeffer, M.D., Ph.D., Professor of Medicine, Harvard Medical School; Senior Physician in Cardiology at Brigham and Women's Hospital, at the Late Breaking Clinical Trials session (Room Hall A) at the American College of Cardiology (ACC) Annual Scientific Sessions in New Orleans on Tuesday, March 27 at 9:35 AM CDT.

Webcast and Conference Call Details
Date: March 27, 2007
Time: 4:00 PM EDT (3:00 PM CDT)
Dial in: Domestic - 877-407-8031
International - 201-689-8031
Replay Dial in: Domestic - 877-660-6853
International - 201-612-7415
Replay Codes: Account # 286
Conference ID# 235811

This event will be accessible on the AtheroGenics website at:

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. AtheroGenics' lead compound, AGI-1067, is being evaluated as an oral therapy for the treatment of atherosclerosis, in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit

Contact Information